Use of triplex CMV vaccine in CAR T cell therapy
AssigneeCity of Hope
InventorsDon J. Diamond, Xiuli Wang, Stephen J. Forman
Life of this patent
Estimating the term…
Abstract
A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.
Claims10
A method for treating a patient suffering from lymphoma expressing CD19 comprising:
- (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) targeted to CD19 and a T cell receptor that binds a cytomegalovirus (CMV) antigen pp65;
- (b) administering the composition of part (a) to the patient;
- and
- (c) administering to the patient a viral vector encoding:
- (i) CMV pp65 and
- (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5).
Dependencies are inferred from the claim text.